Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease
Year: 2019
Type: review
Abstract: )-2-hydroxyglutarate, which in turn inhibits αKG-dependent dioxygenase function, resulting in a global hypermethylation phenotype, increased tumor cell multipotency, and malignancy. Recent studies identified wild-type IDHs as critical regulators of normal organ physiology and, when transcriptionally induced or down-regulated, as contributing to cancer and neurodegeneration, respectively. We describe how mutant and wild-type enzymes contribute on molecular levels to disease pathogenesis, and discuss efforts to pharmacologically target IDH-controlled metabolic rewiring.
Source: Science Advances
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,500
Awards: Nucleic Acid-Based Nanoconstructs for the Treatment of Cancer, Medical Scientist Training Program, Northwestern University Clinical and Translational Science Institute (NUCATS), Nanomaterials for Cancer Diagnostics and Therapeutics, Systemic RNA interference to reactivate p53 tumor suppression, SPORE for Translational Approaches to Brain Cancer, Carcinogenesis Training Program
OpenAlex ID: W2946454907
